The estimated Net Worth of Chirfi Guindo is at least $17.6 Millón dollars as of 5 August 2024. Mr. Guindo owns over 36,901 units of Biogen Inc stock worth over $11,503,619 and over the last 7 years he sold BIIB stock worth over $1,358,280. In addition, he makes $4,694,520 as Executive Vice President, Head of Global Marketing y Market Access and Customer Innovation at Biogen Inc.
Chirfi has made over 10 trades of the Biogen Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 36,901 units of BIIB stock worth $4,250,995 on 5 August 2024.
The largest trade he's ever made was exercising 36,901 units of Biogen Inc stock on 5 August 2024 worth over $4,250,995. On average, Chirfi trades about 4,885 units every 115 days since 2017. As of 5 August 2024 he still owns at least 57,781 units of Biogen Inc stock.
You can see the complete history of Mr. Guindo stock trades at the bottom of the page.
Chirfi Guindo has served as an Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation of Biogen Inc. Prior to joining Biogen, Mr. Guindo has spent 27 years in the global pharmaceutical industry and has held several leadership positions at Merck, a pharmaceutical company, in Canada, the U.S., France, Africa and the Netherlands. He worked in several disciplines including Finance, Sales & Marketing, General Management and Global Strategy/Product Development in specialty, acute and hospital care. Most recently Mr. Guindo was Vice President and Managing Director and President and Managing Director of Merck Canada from October 2014 to November 2017. From January 2011 to October 2014, he was Vice President and General Manager, Global HIV Franchise at Merck.
As the Executive Vice President, Head of Global Marketing y Market Access and Customer Innovation of Biogen Inc, the total compensation of Chirfi Guindo at Biogen Inc is $4,694,520. There are 3 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Chirfi Guindo is 53, he's been the Executive Vice President, Head of Global Marketing y Market Access and Customer Innovation of Biogen Inc since 2017. There are 19 older and 4 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.
Chirfi's mailing address filed with the SEC is MERCK & CO., INC., 126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner y Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: